Last reviewed · How we verify
R-Gene 10 (ARGININE)
R-Gene 10 (arginine) is a small molecule drug developed by Pharmacia and Upjohn, targeting nitric oxide synthase, inducible. It is classified as an arginine hydrochloride and was FDA-approved in 1973 for diagnostic testing of growth hormone secretion and renal radiation exposure from lutetium (177Lu) oxodotreotide. The drug has a bioavailability of 68% but lacks generic manufacturers due to its off-patent status. R-Gene 10 works by increasing the levels of arginine in the body, which in turn stimulates the production of nitric oxide. This drug is no longer under patent protection.
At a glance
| Generic name | ARGININE |
|---|---|
| Sponsor | Pfizer |
| Drug class | arginine hydrochloride |
| Target | Nitric oxide synthase, inducible |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1973 |
Approved indications
- Diagnostic Test for Growth Hormone Secretion
- Renal radiation exposure from Lutetium (177Lu) oxodotreotide
Common side effects
Key clinical trials
- DDAVP for Pituitary Adenoma (NA)
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- Pre-Surgical Immunonutrition's Effect on Colorectal Surgery (NA)
- 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer (PHASE1,PHASE2)
- Effects of L-arginine and Liposomial Vitamin C on Severe Copd Patients Undergoing Pulmonary Rehabilitation. (NA)
- Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial (PHASE3)
- Effect of a Food for Special Medical Purposes on Muscle Mass Preservation During GLP-1 RAs Weight Loss Treatment (NA)
- Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- R-Gene 10 CI brief — competitive landscape report
- R-Gene 10 updates RSS · CI watch RSS
- Pfizer portfolio CI